HU Group’s Fujirebio to acquire assays developer ADx NeuroSciences
ADx NeuroSciences will expand its portfolio of advanced biomarkers and antibodies after the deal’s completion.

ADx NeuroSciences will expand its portfolio of advanced biomarkers and antibodies after the deal’s completion.
The company has two studies in progress, LEVANTIS-0087A for MCED and AURORAX-0087A for kidney cancer recurrence.
M.I.Tech has developed a family of conformable, self-expanding metal stents called HANAROSTENT.
The Fassier-Duval Telescopic Intramedullary System corrects deformity of long bones while preventing or stabilising fractures.
The transaction is expected to expand ResMed’s SaaS business footprint outside the US.
Through the acquisition, BD will have access to a new pharmacy automation market segment worth $600m.
The test identifies gene expression profiles that indicate specific cancers by interrogating mRNA from a whole blood sample.
The device was shown to boost survival and insulin secretion of cells in preclinical models.
Thank you for subscribing to Medical Device Network